Biotech of the week: Vivia Biotech, the Spanish Pioneer in Personalised Medicine

This week we leave the cold winds of Sweden and head south, to warmer weather and say ¡Hola! to Spain and the location for this week, Madrid. This vibrant city is famous for one of the best football teams in the world, the oldest restaurant in the world (opened in 1725!) and is home to the biotech of the week: Vivia Biotech.


City: Madrid

Founded: 2007

Employees: 30 (12/2015)

Financial Data: €11.2M Total Raised (as of 12/2015)

CEO: 

vivia ceo

ANDRÉS BALLESTEROS, CEO (CC Vivia Biotech)

Mission: Vivia Biotech has one primary focus and that is personalised medicine, through screening and profiling of thousands of existing drugs directly on a patient’s biological sample, to conclude the best course of action. They achieve this using their technology, Exvitech, which enables ex-vivo analysis of drugs/drug combinations on patient samples within 48 hours.

Vivia Biotech hope to develop a personalised medicine kit for hematologic cancers (e.g. leukemia, lymphoma etc) which will be able to predict the best treatment for each individual.

Comments: Personalised medicine could be the future of medicine but looks more like a dream right now. Vivia Biotech seems clearly on the way of making personalised medicine a bit more of a reality, and this could have an huge impact on healthcare.

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and its' freely accessible content.